PTGS2 and cancer: Here we investigated the potential of the NSAID licofelone, a dual COX-2/5-LO inhibitor, to reduce the frequency of immune-suppressive cells in lymphatic organs and to stimulate antitumor immunity when used in combination with a cancer vaccine.